Expert Opinion

Dual Antiplatelet Therapy in Coronary Artery Disease: Comparison Between ACC/AHA 2016 and ESC 2017 Guidelines

Register or Login to View PDF Permissions
Permissions× For commercial reprint enquiries please contact Springer Healthcare:

For permissions and non-commercial reprint enquiries, please visit to start a request.

For author reprints, please email
Information image
Average (ratings)
No ratings
Your rating


Dual antiplatelet therapy (DAPT) is integral to the management of coronary artery disease (CAD) but there remains uncertainty as to the optimal approach for balancing an individual’s risk of atherothrombotic events versus their risk of bleeding complications. A myriad of clinical trials have investigated how factors such as antiplatelet selection or duration of treatment can affect outcomes in both stable CAD and acute coronary syndromes. To aid clinicians in the challenge of applying trial findings to the circumstances of individual patients, the American College of Cardiology/American Heart Association and European Society of Cardiology have released focused updates on prescribing DAPT in CAD. While the two guidelines agree on many issues, there are some differences in the recommendations. This article highlights those differences and provides comment on their aetiology.

Disclosure:The author has no conflicts of interest to declare.



Published online:

Correspondence Details:Christopher Floyd, Clinical Research Facility, Fourth Floor, St Thomas’ Hospital, London SE1 7EH, UK. E:

Open Access:

This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

Antiplatelet therapy represents a key pharmacological pillar for the prevention of atherothrombotic events. Aspirin, the primogenial antiplatelet agent, has been shown to reduce the incidence of recurrent major adverse cardiovascular events (MACE) by approximately one-fifth.1 Dual antiplatelet therapy (DAPT), usually aspirin in combination with a P2Y12 inhibitor, provides greater platelet inhibition resulting in an incremental reduction in the risk of MACE but at the cost of an increased risk of major bleeding.

Prescribers are faced with the challenge of identifying where this risk:benefit ratio lies for each individual patient, and producing a tailored approach based on clinical presentation, management strategy and patient characteristics. To assist clinicians in the challenge of applying trial findings to the circumstances of individual patients, the American College of Cardiology/American Heart Association (ACC/AHA) and European Society of Cardiology (ESC) released focused updates on prescribing DAPT in coronary artery disease (CAD).2,3

To aid clinical decision-making, the updates provide helpful flowcharts that stratify patients according to presentation (stable CAD versus acute coronary syndrome [ACS]), management strategy (conservative versus interventional), and perceived bleeding risk. Differences between the two publications can be largely attributed to the 17 months between publications and, to a lesser extent, differences in the methodology for grading evidence, and the scope of each update. With no paradigm-shifting publications in this intervening period, it is unlikely that following one set of recommendations would lead to substantially different patient outcomes compared with the other.

Duration of DAPT: Ischaemic Versus Bleeding Risk

The two guidelines generally agree on the two key issues faced by clinicians: the selection and the duration of P2Y12 inhibition. In broad terms, prasugrel and ticagrelor are recommended for those at higher risk of ischaemic events (ACS compared with CAD) given that pharmacokinetic factors result in greater platelet inhibition compared with clopidogrel.4 The standard duration of DAPT for patients with ACS is ≥12 months, and ≥6 months for those with CAD undergoing intervention. These durations may be lengthened or shortened depending on perceived ischaemic or bleeding risk, and the decision-making behind such decisions is a major focus of the two updates.

The ACC/AHA update includes a list of clinical and procedural factors associated with increased ischaemic risk, increased risk of stent thrombosis and increased bleeding risk, but acknowledges that many patients will have risk factors across categories and hence identifying where the balance lies for each individual remains challenging. Both updates present the DAPT score as a tool for assessing the risk:benefit ratio of >12 months DAPT after percutaneous coronary intervention (PCI).5,6

The DAPT score can be used after the completion of 12 months of uneventful DAPT after PCI (i.e. those free from repeat ischaemic events or moderate/severe bleeding) and is calculated by summation of points attributed to nine variables, as follows.6 For the first variable, age, the score awards −2 points for age ≥75 years, −1 point for age 65 to <75 years and 0 points for age <65 years; it then awards 1 point each for current cigarette smoker; diabetes; MI at presentation; prior PCI or MI; paclitaxel-eluting stent; and stent diameter <3 mm; and then 2 points each for congestive heart failure or left ventricular ejection fraction <30%; and vein graft stent. The score ranges from −2 to 10 points, with a score ≥2 indicating longer DAPT, and a score <2 indicating standard DAPT.6

The later publication date for the ESC update enabled it to also include the Predicting Bleeding Complication in Patients Undergoing Stent Implantation and Subsequent Dual Antiplatelet Therapy (PRECISE-DAPT) score, which uses five patient-derived variables (haemoglobin; white blood cell count; age; creatinine clearance; and prior bleeding) to determine whether shorter (3–6 months) or standard/longer (12–24 months) DAPT may be beneficial after PCI based on bleeding risk.7 This score uses a nomogram to provide a decision-making cut-off regarding shorter or standard/longer DAPT. Although it is more challenging to calculate manually (available at, it does have the advantage that it is performed at the time of coronary stenting, rather than after 12 months of DAPT. Decisions regarding the duration of DAPT therefore do not rely on assessments at follow-up appointments, which may not always occur in a timely manner. Crucially, neither the DAPT nor the PRECISE-DAPT scores have been tested in prospective randomised controlled trials (RCTs), and many of the RCTs comparing the different durations of DAPT have wide non-inferiority margins and low rates of ischaemic events. Consequently, most recommendations for the duration of DAPT are graded as class II (i.e. a particular duration should ‘be considered’ or ‘is reasonable’), highlighting the lack of conclusive evidence.

Prevention of Gastrointestinal Bleeding

Gastrointestinal (GI) bleeding represents the most common serious bleeding complication from long-term antiplatelet therapy, and so co-prescription of proton pump inhibitors (PPIs) is recommended.8 The ACC/AHA recommends PPIs only for those at risk of bleeding (prior GI bleeding, advanced age and concomitant use of warfarin, steroids or non-steroidal anti-inflammatory drugs), whereas the ESC recommends PPIs for all prescribed DAPT. The difference in the recommendations is due to their respective interpretation of a large clinical trial that demonstrated a pharmacokinetic interaction between clopidogrel and omeprazole, but without an impact on cardiovascular events.9 However, given the known cytochrome pharmacokinetic interaction, it remains prudent to avoid co-prescription of clopidogrel with omeprazole/esomeprazole if possible.4 No such interaction has been identified between PPIs and prasugrel or ticagrelor.

Utility of Platelet Function Testing

The personalisation of antiplatelet therapy based on platelet function testing has been an aspiration following observations that high and low platelet reactivity while prescribed P2Y12 inhibitors predicts ischaemic and bleeding risk, respectively.10 Despite significant progresses in understanding the aetiology of poor response to antiplatelet agents,11,12 the updates are unable to make recommendations following neutral results from RCTs using platelet function-guided therapy, and a lack of RCTs investigating genome-led strategies.13–15

Since publication of the two guidelines, several studies investigating antiplatelet de-escalation (usually from prasugrel or ticagrelor to clopidogrel) have been reported. The 2018 ESC guidelines on myocardial revascularisation state that de-escalation based on platelet function testing may be considered as an alternative to 12 months of potent platelet inhibition, for which bleeding risk is high.16 However, it refers back to a 2017 consensus statement, which, although offering advice regarding drug dose/timings when switching, does not provide any practical advice on patient selection for the use of platelet function testing.17 This uncertainty around the clinical utility of platelet function testing and the efficacy of antiplatelet de-escalation is reflected in a recent meta-analysis highlighting that although de-escalation from ticagrelor to clopidogrel commonly occurs in real-world practice, the profile of patients suitable for de-escalation, the impact of de-escalation on adverse clinical outcomes, and how this is affected by the timing after index ACS warrant further large-scale investigation.18

Combination Antiplatelet and Anti-thrombotic Therapy

Combination of antiplatelet therapy and anti-thrombotic therapy is increasingly indicated given that AF and CAD commonly co-exist, and this adds additional complexity to the risk:benefit assessment.19,20 This topic lies outside the scope of the ACC/AHA update, and although recommendations were made by the ESC update this has largely been superseded by a recent European consensus document that recommends use of the CHA2DS2-VASc and HAS-BLED scores when assessing risk:benefit ratio in AF, and a general preference for prescribing clopidogrel rather than prasugrel or ticagrelor.21 In individuals with high atherothrombotic risk and low bleeding risk, triple therapy (aspirin, clopidogrel and oral anticoagulant) can be prescribed for up to 6 months, with dual therapy (clopidogrel plus oral anticoagulant) continued for up to 12 months after PCI. When there are concerns about high bleeding risk, the duration of triple therapy can be shortened to 1 month or removed altogether. In all cases, once 12 months of dual therapy has been completed, individuals can continue oral anticoagulant as monotherapy.21

Future Recommendations

The evidence base for antiplatelet therapy continues to develop; and recently published or ongoing studies investigating the routine use of anticoagulants, aspirin dosing regimens, P2Y12 monotherapy, direct prasugrel versus ticagrelor comparisons, and switching between P2Y12 inhibitors will all inform future updates and continue the push towards personalised medicine as our understanding of individual risk:benefit ratio evolves.


  1. Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849–60.
    Crossref | PubMed
  2. Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2016;68:1082–115.
    Crossref | PubMed
  3. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018;39:213–60.
    Crossref | PubMed
  4. Floyd CN, Passacquale G, Ferro A. Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications. Clin Pharmacokinet 2012;51:429–42.
    Crossref | PubMed
  5. Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014;371:2155–66.
    Crossref | PubMed
  6. Yeh RW, Secemsky EA, Kereiakes DJ, et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA 2016;315:1735–49.
    Crossref | PubMed
  7. Costa F, van Klaveren D, James S, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 2017;389:1025–34.
    Crossref | PubMed
  8. Agewall S, Cattaneo M, Collet JP, et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J 2013;34:1708–13, 13a–13b.
    Crossref | PubMed
  9. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363:1909–17.
    Crossref | PubMed
  10. Aradi D, Kirtane A, Bonello L, et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 2015;36:1762–71.
    Crossref | PubMed
  11. Floyd CN, Ferro A. Mechanisms of aspirin resistance. Pharmacol Ther 2014;141:69–78.
    Crossref | PubMed
  12. Floyd CN, Ferro A. Antiplatelet drug resistance: molecular insights and clinical implications. Prostaglandins Other Lipid Mediat 2015;120:21–7.
    Crossref | PubMed
  13. Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012;367:2100–9.
    Crossref | PubMed
  14. Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 2012;59:2159–64.
    Crossref | PubMed
  15. Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011;305:1097–105.
    Crossref | PubMed
  16. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 2019;40:87–165.
    Crossref | PubMed
  17. Angiolillo DJ, Rollini F, Storey RF, et al. International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies. Circulation 2017;136:1955–75.
    Crossref | PubMed
  18. Angiolillo DJ, Patti G, Chan KT, et al. De-escalation from ticagrelor to clopidogrel in acute coronary syndrome patients: a systematic review and meta-analysis. J Thromb Thrombolysis 2019;48:1–10.
    Crossref | PubMed
  19. Bhatnagar P, Wickramasinghe K, Williams J, et al. The epidemiology of cardiovascular disease in the UK 2014. Heart 2015;101:1182–9.
    Crossref | PubMed
  20. Floyd CN, Ferro A. Indications for anticoagulant and antiplatelet combined therapy. BMJ 2017;359:j3782.
    Crossref | PubMed
  21. Lip GYH, Collet JP, Haude M, et al. Management of antithrombotic therapy in AF patients presenting with ACS and/or undergoing PCI. Eur Heart J 2018;39:2847–50.
    Crossref | PubMed